Welcome to our dedicated page for Terns Pharmaceuticals SEC filings (Ticker: TERN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Terns Pharmaceuticals filings document the company’s clinical-stage oncology disclosures, capital structure, and completed transition from Nasdaq-listed issuer to Merck subsidiary. Recent Form 8-K reports cover TERN-701 regulatory updates, including FDA Breakthrough Therapy Designation for chronic myeloid leukemia, license and intellectual-property arrangements involving the program, operating results, and material definitive agreements.
The filing record also includes the acquisition-completion Form 8-K and Nasdaq Form 25 for removal of Terns common stock from listing and Section 12(b) registration. These documents record the treatment of TERN common stock, exchange registration status, governance and shareholder-related disclosures, financial statement exhibits, and other material-event reporting associated with the company’s public-company status.
Commodore Capital entities and two individuals report beneficial ownership of 4,650,000 shares of Terns Pharmaceuticals, Inc. common stock, representing 5.3% of the 87,511,048 shares outstanding used as the denominator. The filing on Schedule 13G lists Commodore Capital LP (Delaware), Commodore Capital Master LP (Cayman Islands), and principals Robert Egen Atkinson and Michael Kramarz as filers. The Firm is the investment manager to Commodore Master and the two individuals are managing partners exercising investment discretion. The filing includes a certification that the shares were not acquired to change or influence control of the issuer.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin filed an amendment to Schedule 13G reporting beneficial ownership of 7,495,000 shares of Terns Pharmaceuticals common stock, representing 8.58% of the outstanding shares. The filing states the position is held with shared voting and shared dispositive power and that there is no sole voting or dispositive power. The ownership calculation references 87,337,801 shares outstanding as of May 2, 2025. The filing includes a certification that the shares were not acquired to change or influence control.